

AMGEN Safety Net Foundation

As of January 1, 2024, the products listed below will have a Federal Poverty Limit (FPL) requirement of 300%:

- Aimovig® (ereenumab-aooe)
- AMJEVITA™ (adalimumab-atto)
- AVSOLA® (infliximab-axxq)
- Cortanor® (ivabradine)
- ENBREL® (etanercept)
- EVENITY® (romosozumab-aqqg)
- Otezla® (apremilast)
- Parsabiv® (etelcalcetide)
- Prolia® (denosumab)
- Repatha® (evolocumab)

FAQs

When does this update take effect?

This will take effect as of January 1, 2024.

Who will be affected with this update?

NEW enrollments will be reviewed under the FPL of 300%.

What if I am re-enrolling for 2024?

Re-enrolling patients will be considered under an income limit eligibility criteria that is up to 500% of the FPL.

What happens in 2025?

For the 2025 enrollment year ALL patients will be reviewed under an FPL of 300% for the products listed above.

As of January 1, 2024, ASNf will no longer enroll patients for NEUPOGEN® (filgrastim) and Neulasta® (pegfilgrastim). Currently enrolled patients will continue to receive support for their NEUPOGEN® (filgrastim) or Neulasta® (pegfilgrastim) through their eligibility end date.

- NEUPOGEN® (filgrastim)
- Neulasta® (pegfilgrastim)

FAQs

What if my enrollment in Amgen Safety Net Foundation (ASNf) already continues into 2024?

ASNf will continue to support you with your NEUPOGEN® or Neulasta® through the date your eligibility ends in 2024.

Can I still enroll or re-enroll in 2024?

No, ASNf will no longer be accepting any enrollments or re-enrollments for NEUPOGEN® or Neulasta® as of January 1, 2024.

When is the last day I can enroll or re-enroll for NEUPOGEN® or Neulasta®?

The last day ASNf will accept any enrollments is Friday, December 15, 2023.

When is the last day my physician can administer NEUPOGEN® or Neulasta® to me?

ASNf cannot provide medical advice, including product administration. ASNf will continue to support you with NEUPOGEN® or Neulasta® through your eligibility end date.

When is my eligibility end date?

For questions about your eligibility, you or your prescribing physician can call ASNf at 1-888-401-4931. We are available Monday through Friday 8 a.m. to 8 p.m. Eastern Time (ET).

Are there other patient support resources available for NEUPOGEN® or Neulasta®?

Please contact Amgen SupportPlus for more information at 1-866-264-2778 Monday through Friday from 9 a.m. to 8 p.m. Eastern Time (ET).

Who do I contact if I have further questions regarding ASNf support for NEUPOGEN® or Neulasta®?

For questions regarding ASNf support for NEUPOGEN® or Neulasta® you or your patient can call ANSF at 1-888-401-4931.

FOR PROVIDERS ONLY

- NEUPOGEN® (filgrastim)
 - Neulasta® (pegfilgrastim)
-

FAQs**When is the last day I can administer NEUPOGEN® or Neulasta® to my patients?**

ASNF cannot provide medical advice, including product administration. ASNF will continue to support your approved NEUPOGEN® or Neulasta® patients through their eligibility end date.

Can I still submit a product replacement request form for NEUPOGEN® or Neulasta® in 2024?

Yes, replacement orders can still be submitted in 2024 for enrolled patients. Providers must still follow all regular product replacement request form guidelines. You can navigate to this form by going to AmgenSafetyNetFoundation.com and going to RESOURCES > FORMS and selecting the NEUPOGEN® or Neulasta® tile.

Are NEUPOGEN® or Neulasta® product replacement request forms still available on the Amgen Safety Net Foundation website?

Yes, the NEUPOGEN® or Neulasta® product replacement request forms are still available on the Amgen Safety Net Foundation website. You can navigate to this form by going to AmgenSafetyNetFoundation.com and going to RESOURCES > FORMS and selecting the NEUPOGEN® or Neulasta® tile.